Michael Luo

Antares Pharma's Otrexup Will Gain FDA Approval And Generate Positive EPS

Investment Thesis

Antares Pharma (NASDAQ:ATRS) is an under the radar biotech company which is starting to make the significant transformation of a royalty based revenue generating company to a fully fledged proprietary product revenue generating bonafide biotech. Its first proprietary product Otrexup has an FDA PDUFA date of October 14, 2013. I am confident that the FDA will approve Otrexup. The biggest bear case against Antares is seeing if management can execute its plan and generate Otrexup revenue, which can organically fund the promising pipeline. This article will feature my investing thesis on why Otrexup will gain FDA approval, why Otrexup commercialization will be incredibly successful and how Antares management will be able to leverage Otrexup gains to...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
PRO Top long ideas returned 21.7% in 2016**
"As a PRO member, we get uniquely valuable perspective that go beyond our quantiative analysis... We rely on PRO to get beyond the numbers quickly and add much needed perspective. It keeps me ahead of the next big thing. - Mark Choate, Malaga Cove Capital"
Mark Choate, Malaga Cove Capital
"Contributors (writers and commentators), often have a long history in the secuirities they opine on and some are clearly well positioned industry participants with detailed industry views that can help provide color on where the skeletons are buried in a particular secuirity and/or industry."
Jim Roumell, Roumell Asset Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details